MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Biogen ROE Ratio 2011-2025 | BIIB
Annual ROE Ratio Biogen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.76 | 7.85 | 22.76 | 14.28 | 37.44 | 44.14 | 34.0 | 20.15 | 30.53 | 37.84 | 27.14 | 21.6 | 19.82 | 19.21 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.14 | 7.85 | 24.75 |
Quarterly ROE Ratio Biogen
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.06 | 10.05 | 8.16 | 9.88 | 9.02 | 15.32 | 24.68 | 29.51 | 20.51 | 23.54 | 17.68 | 12.93 | 15.08 | 18.42 | 21.95 | 32.19 | 37.39 | 44.83 | 49.86 | 46.65 | 44.13 | 40.6 | 40.09 | 35.54 | 33.98 | 24.36 | 23.0 | 23.2 | 20.13 | 27.84 | 26.62 | 28.43 | 30.5 | 34.03 | 35.82 | 37.07 | 37.84 | 37.14 | 34.77 | 31.49 | 27.15 | 24.28 | 22.01 | 21.09 | 21.6 | 20.49 | 20.56 | 20.43 | 19.82 | 20.3 | 20.05 | 18.98 | 19.21 | 5.48 | 4.48 | 4.58 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.86 | 4.48 | 24.93 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-68.71 | $ 4.76 | -0.73 % | $ 790 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-84.9 | $ 3.01 | -1.15 % | $ 233 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 1.16 | -0.85 % | $ 6.33 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 209.37 | -1.62 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-507.47 | $ 0.52 | -44.08 % | $ 144 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.29 | 6.3 % | $ 7.92 B |  Australia |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-92.27 | $ 1.16 | -8.66 % | $ 1.71 M | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 94.21 | -0.86 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
21.78 | $ 27.0 | 0.7 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 0.22 | 24.23 % | $ 479 M |  Israel |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 9.49 | 0.11 % | $ 139 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-1373.04 | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
16.2 | $ 583.31 | -1.33 % | $ 44.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.47 | -2.37 % | $ 15.5 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | $ 92.76 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 12.37 | - | $ 814 M | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 9.03 | 0.28 % | $ 1.48 B | Britain |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 10.71 | -0.88 % | $ 693 M | USA |
 |
Celldex Therapeutics
CLDX
|
-21.13 | $ 26.13 | -2.63 % | $ 1.68 M | USA |
 |
Cellectar Biosciences
CLRB
|
282.15 | $ 2.55 | -7.47 % | $ 31.2 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-64.24 | - | - | $ 7.29 B | USA |